Yahoo Web Search

Search results

1. www.alnylam.comAlnylam® Pharmaceuticals

   www.alnylam.com

   • Cached

   Alnylam® Pharmaceuticals. Disrupting Disease ™. Our innovative RNAi therapeutics silence the genes that cause human disease. Learn More ›. People First. Our medicines, and actions as a company are tackling complex health and societal challenges. Learn More ›. Broad Impact.

   • Careers

     CAREERS AT ALNYLAM This Is YOUR Moment. This is the moment...

     Career Opportunities

     · Who We Are

   • Pipeline

     The following content may not be associated with Alnylam...

     Clinical Trials

     · Events & Presentations

     · Press Releases

   • Our Products

     Find information about Alnylam's pharmaceutical products:...

     About Alnylam

     · Our News

   • Contact

     Medical Information. For medical information, please call:...

   • Leadership

     Prior to joining Alnylam, Tim was a member of the senior...

   • The Science of RNAi

     How siRNAs Work. When the siRNA duplex is delivered into the...

   • Scientific Advisory Board

     The following content may not be associated with Alnylam...

   • Intellectual Property

     Our Science. INTELLECTUAL PROPERTY. Alnylam protects its...

   • Investor Relations

     The Investor Relations website contains information about...

     Aug 03, 2022 Press Release

     · Analyst Coverage

     · Annual Meetings

     · Investor Toolkit

     · Financial Information

     · Stock Information

2. en.wikipedia.org › wiki › Alnylam_PharmaceuticalsAlnylam Pharmaceuticals - Wikipedia

   en.wikipedia.org › wiki › Alnylam_Pharmaceuticals

   • Cached

   Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

   • Founded: 2002; 21 years ago
   • Headquarters: Cambridge, Massachusetts, U.S.

   • Number of employees: 1,323 (2019)
   • Revenue: US$219.75 million (2019), US$74.91 million (2018)

3. www.alnylam.com › about-alnylamAbout Alnylam® Pharmaceuticals

   www.alnylam.com › about-alnylam

   • Cached

   We are advancing a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.

   • 
   • 
   • 
   • 

4. People also ask

   Who is Alnylam Pharmaceuticals?

   • Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

   Alnylam Pharmaceuticals - Wikipedia

   en.wikipedia.org/wiki/Alnylam_Pharmaceuticals

   See all results for this question

   What happened to Alnylam Pharmaceuticals?

   • CAMBRIDGE, Mass., February 15, 2024 -- ( BUSINESS WIRE )-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2023 and reviewed recent business highlights. "2023 was a year of strong execution at Alnylam.

   Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023

   finance.yahoo.com/news/alnylam-pharmaceuticals-reports-fourth-quarter-130000144.html

   See all results for this question

   What products does Alnylam sell?

   • Receive news and updates on the work at Alnylam that affects you most. Find information about Alnylam's pharmaceutical products: ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and AMVUTTRA® (vutrisiran).

   RNAi Therapeutics | Our Approved Products - Alnylam Pharmaceuticals

   www.alnylam.com/our-products

   See all results for this question

   What are Alnylam's commercial RNAi therapeutic products?

   • Alnylam’s commercial RNAi therapeutic products are ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), and Leqvio (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis.

   Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023

   finance.yahoo.com/news/alnylam-pharmaceuticals-reports-fourth-quarter-130000144.html

   See all results for this question

5. finance.yahoo.com › news › alnylam-pharmaceuticalsAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year ...

   finance.yahoo.com › news › alnylam-pharmaceuticals

   • Cached

   Feb 15, 2024 · CAMBRIDGE, Mass., February 15, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth...

6. www.google.com › finance › quoteAlnylam Pharmaceuticals, Inc. (ALNY) Stock Price & News ...

   www.google.com › finance › quote

   • Cached

   Alnylam Pharmaceuticals, Inc. $147.70. Apr 16, 8:18:47 AM GMT-4 · USD · NASDAQ · Disclaimer. 1D. 5D. 1M. 6M. YTD. 1Y. 5Y. MAX. search Compare to. Arrowhead Pharmaceuticals Inc. $24.01....

7. Images

   • 
   • 
   • 

   View all